Analyst Consensus ?
ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%
Ascendis Pharma A/S · ASND · FY2024 Q2 · Calendar Q3 2024
Ascendis: YORVIPATH approval advances launch plans as SKYRTOFA guidance holds
The current analysis supports a mixed but constructive operating picture: YORVIPATH approval and pipeline progress add potential growth drivers, while SKYRTOFA revenue adjustments, payer dynamics, launch execution, and milestone timing remain important constraints.
Reported After market closeNASDAQHealthcare
$15.18B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-2.05
Consensus $-1.54
EPS surprise
-33.1%
Reported versus consensus
Reported revenue
$38.9M
Consensus $113.0M
Revenue surprise
-65.6%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-11.3%
Event window
SPY move
-0.2%
Same window
Abnormal move
-11.1%
Stock minus SPY
Volume
7.4×
Versus trailing sessions
Subsequent drift
+22.4%
Up to 20 sessions
ASNDSPY benchmark
Ask FN2 about ASND FY2024 Q2
Transcript, numbers and history already loaded
Why did ASND fall 11.3% after missing EPS estimates in FY2024 Q2?What changed in ASND's guidance and outlook in FY2024 Q2?Give me the bull and bear case for ASND after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
YORVIPATH received FDA approval and a U.S. launch was anticipated for Q1 2025. The company also disclosed a $150 million capped royalty-financing agreement, while SKYRTOFA volume doubled year over year but revenue was affected by market-access true-ups.
Guidance delta
Management maintained full-year SKYRTOFA revenue guidance at EUR220–240 million, despite Q2 market-access true-ups.
Key takeaways
- YORVIPATH received FDA approval, with a U.S. launch anticipated in Q1 2025.
- SKYRTOFA volume doubled year over year, while revenue was affected by market-access true-ups.
- TransCon CNP pivotal data and oncology updates were identified as near-term milestones.
Management priorities
- Execute the U.S. YORVIPATH launch and patient-support programs
- Advance SKYRTOFA label expansion and commercial execution
- Deliver TransCon CNP and oncology pipeline milestones
Follow ASND with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$243.37Current
$136Low
$270.03Average
$344High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 26, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Sep 25, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 15, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Sep 2, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Sep 1, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 31, 2026 |
| Jefferies | Buy | Buy | Maintain | Aug 31, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Aug 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 31, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 14, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| UBS | Buy | Buy | Maintain | Aug 8, 2025 |
| Citigroup | Buy | Buy | Maintain | Aug 8, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2025 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 28, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 17, 2023 |
| Cowen & Co. | Perform | Market Perform | Maintain | Jan 6, 2022 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 1, 2021 |
| Berenberg | Buy | Buy | Maintain | Dec 17, 2020 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Jan 24, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 30, 2018 |
| Bank of America | Buy | Buy | Maintain | Jan 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $243.37. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $269 | $227 | +10.5% | Oct 15, 2026 |
| UBS | Analyst unavailable | $344 | $239.77 | +41.3% | Sep 16, 2026 |
| Raymond James | Martin Auster | $287 | $264.92 | +17.9% | Sep 15, 2026 |
| H.C. Wainwright | Analyst unavailable | $344 | $260.81 | +41.3% | Sep 10, 2026 |
| Oppenheimer | Leland Gershell | $312 | $260.25 | +28.2% | Sep 1, 2026 |
| Morgan Stanley | Maxwell Skor | $273 | $263.04 | +12.2% | Sep 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $265.26 | +35.6% | Aug 31, 2026 |
| Stifel Nicolaus | Analyst unavailable | $326 | $265.32 | +34.0% | Aug 31, 2026 |
| UBS | Analyst unavailable | $345 | $247.91 | +41.8% | Aug 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $345 | $250.25 | +41.8% | Aug 27, 2026 |
| BMO Capital | Analyst unavailable | $319 | $248.85 | +31.1% | Aug 18, 2026 |
| RBC Capital | Luca Issi | $290 | $247.06 | +19.2% | Aug 14, 2026 |
| Barclays | Analyst unavailable | $329 | $246.23 | +35.2% | Aug 14, 2026 |
| Jefferies | Kelly Shi | $333 | $246.23 | +36.8% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $253.6 | +13.0% | Jul 23, 2026 |
| RBC Capital | Analyst unavailable | $280 | $267.92 | +15.1% | Jul 7, 2026 |
| Evercore ISI | Analyst unavailable | $329 | $241.83 | +35.2% | May 15, 2026 |
| Barclays | Analyst unavailable | $345 | $238.66 | +41.8% | May 11, 2026 |
| Wells Fargo | Analyst unavailable | $326 | $246.14 | +34.0% | May 8, 2026 |
| Jefferies | Analyst unavailable | $262 | $237.35 | +7.7% | Mar 5, 2026 |
| Stifel Nicolaus | Alex Thompson | $332 | $241.38 | +36.4% | Mar 4, 2026 |
| Wolfe Research | Kalpit Patel | $260 | $231.46 | +6.8% | Mar 2, 2026 |
| Cantor Fitzgerald | Li Watsek | $300 | $231.43 | +23.3% | Mar 2, 2026 |
| Evercore ISI | Josh Schimmer | $324 | $234.07 | +33.1% | Mar 2, 2026 |
| Goldman Sachs | Paul Choi | $255 | $233.5 | +4.8% | Mar 2, 2026 |
| Wedbush | Analyst unavailable | $273 | $218.39 | +12.2% | Feb 12, 2026 |
| Oppenheimer | Analyst unavailable | $262 | $217.93 | +7.7% | Feb 12, 2026 |
| Stifel Nicolaus | Alex Thompson | $325 | $218.04 | +33.5% | Feb 12, 2026 |
| Morgan Stanley | Maxwell Skor | $256 | $221.49 | +5.2% | Feb 12, 2026 |
| Barclays | Eliana Merle | $342 | $238.8 | +40.5% | Jan 27, 2026 |
| RBC Capital | Analyst unavailable | $250 | $205.83 | +2.7% | Jan 20, 2026 |
| Wells Fargo | Derek Archila | $330 | $205.83 | +35.6% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $322 | $208.75 | +32.3% | Jan 9, 2026 |
| Stifel Nicolaus | Alex Thompson | $256 | $201.37 | +5.2% | Dec 11, 2025 |
| Cantor Fitzgerald | Li Watsek | $254 | $209.55 | +4.4% | Oct 13, 2025 |
| RBC Capital | Luca Issi | $230 | $191.49 | -5.5% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $180 | $144.08 | -26.0% | Feb 18, 2025 |
| Bank of America Securities | Tazeen Ahmad | $191 | $151.26 | -21.5% | Sep 23, 2024 |
| Evercore ISI | Gavin Clark-Gartner | $205 | $144.97 | -15.8% | Sep 17, 2024 |
| Oppenheimer | Leland Gershell | $190 | $143.9 | -21.9% | Sep 17, 2024 |
| Citigroup | David Lebowitz | $207 | $139.57 | -14.9% | Sep 17, 2024 |
| Wells Fargo | Derek Archila | $289 | $139.57 | +18.7% | Sep 17, 2024 |
| Bank of America Securities | Tazeen Ahmad | $175 | $142.26 | -28.1% | Sep 16, 2024 |
| Goldman Sachs | Paul Choi | $200 | $142.26 | -17.8% | Sep 16, 2024 |
| Citigroup | David Lebowitz | $178 | $118 | -26.9% | Sep 13, 2024 |
| Oppenheimer | Leland Gershell | $180 | $122.4 | -26.0% | Sep 5, 2024 |
| Jefferies | Kelly Shi | $196 | $128.48 | -19.5% | Aug 13, 2024 |
| Stifel Nicolaus | Alex Thompson | $200 | $137.45 | -17.8% | May 30, 2024 |
| Morgan Stanley | Vikram Purohit | $140 | $124.04 | -42.5% | May 15, 2024 |
| Evercore ISI | Josh Schimmer | $191 | $149.89 | -21.5% | Mar 14, 2024 |
| Wells Fargo | Analyst unavailable | $177 | $118.87 | -27.3% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $148 | $111.47 | -39.2% | Nov 15, 2022 |
| Leerink Partners | Analyst unavailable | $148 | $110.26 | -39.2% | Nov 14, 2022 |
| Wedbush | Analyst unavailable | $164 | $110.26 | -32.6% | Nov 14, 2022 |
| Bank of America Securities | Tazeen Ahmad | $161 | $117.44 | -33.8% | Mar 20, 2022 |
| Citigroup | David Lebovitz | $187 | $112.39 | -23.2% | Feb 28, 2022 |
| Cowen & Co. | Yaron Werber | $136 | $121.7 | -44.1% | Jan 6, 2022 |
| Canaccord Genuity | Michelle Gilson | $196 | $126.68 | -19.5% | Jul 7, 2021 |
| Cantor Fitzgerald | Alethia Young | $201 | $134.4 | -17.4% | Jun 14, 2021 |
Track every rating change on ASND the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAscendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Historical context
All ASND earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the ASND recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-26T01:50:40.983249+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-26T01:50:40.980512+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-26. For educational purposes only; not investment advice.